BPC-157

BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids, originally derived as a partial sequence from human gastric juice. It belongs to a class of compounds known as body protection compounds and has been the subject of extensive preclinical research since the early 1990s. In animal models, BPC-157 has been characterized across a broad range of biological assays, including in-vitro wound-assay outcomes and cell-migration kinetics in preclinical models involving muscle, tendon, ligament, and skin cell systems. Its mechanism of action is believed to involve modulation of the nitric oxide (NO) system, upregulation of growth-factor expression (including VEGF and EGF), and interaction with multiple molecular pathways including the FAK-paxillin and JAK-2/STAT-3 signaling cascades.

A substantial body of preclinical literature supports the peptide's role in gastrointestinal cytoprotection in GI epithelial cell models. Studies have shown that BPC-157 can counteract lesions induced by NSAIDs, alcohol, and various cytotoxic agents in gastrointestinal preclinical models, from the esophagus to the colon. The peptide has been characterized in in-vitro endothelial tube-formation (angiogenic) assays, considered central to its activity in tissue-repair research models. Research by Sikiric and colleagues has documented its activity in tissue-repair kinetics for anastomoses, fistulas, and other surgical research-model wounds in rat preclinical systems.

Beyond the gastrointestinal system, BPC-157 has been investigated in neuroprotective assay models. Preclinical studies suggest it may modulate dopaminergic and serotonergic systems, with reported cytoprotection in preclinical cell cultures against damage induced by cuprizone, MPTP, and other neurotoxins. The peptide has also been characterized in bone-fracture tissue-repair research models and in preclinical models counteracting corticosteroid-induced parameter shifts.